

## C U R R I C U L U M   V I T A E

Name: Gabriel I. Barbash, M.D., M.P.H.  
I.D. No.: 30283352  
Faculty: Medicine  
Institution: Tel-Aviv Sourasky Medical Center  
Phone No.: 972 - 3 - 697 4212  
Fax: 972 - 3 - 697 4433  
Home Address: 19 Keren Kayemet St, Givataim, Israel 53221  
Phone No.: 03-6728280  
Date and Place  
of Birth: September 13, 1949, Israel  
I.D.F  
Military Service: Enlisted in 1968

### **A.   EDUCATION**

1969 - 1975   **Hebrew University**, Jerusalem, Hadassah Medical School  
M.D. Degree received December 1975  
1980 - 1984   Residency in Internal Medicine, Tel Aviv Sourasky Medical Center  
Passed the Israeli Board examinations in **Internal Medicine**,  
May 1984, Summa Cum Laude  
1985 - 1986   Clinical - Administrative Residency  
Administration & Cardiology Department  
**Beth Israel Hospital**, Boston, Massachusetts  
1987   Passed the Israeli Board of **Medical Management**  
1991   Passed the Israeli Board of **Occupational Medicine**

### **B.   FURTHER STUDIES**

1983 - 1984   Tel Aviv University Medical School  
One year program, Computers in Medicine  
1984 - 1985   **Harvard University**, School of Public Health  
Master in Public Health with concentration in Health  
Policy and Management, June 1985

**C. ACADEMIC EXPERIENCE**

- 1986 - 1993 Teaching the course on Medical Information Systems in the master program of the Kovens Center for Management of Health Care Systems in the Rekanati School of Business Administration, Tel Aviv University
- 1987 - 1988 Co-coordinator of the course on Bio-medical Ethics in the post-graduate school of the Sackler School of Medicine in Tel Aviv University
- 1988 - 1990 Lecturer in the Department of Epidemiology and Preventive Medicine in the Sackler School of Medicine, Tel Aviv University
- 1989 - 1993 Teaching the course in Epidemiology in the Master program of the Kovens Center for Management of Health Care Systems in the Rekanati School of Business Administration, Tel Aviv University
- 1990 - 1994 Senior lecturer in the Department of Epidemiology and Preventive Medicine in the Sackler School of Medicine, Tel Aviv University
- 1994 - 2001 Associate Professor in the Department of Epidemiology and Preventive Medicine in the Sackler School of Medicine, Tel Aviv University
- 2001 - Professor of Epidemiology and Preventive Medicine in the Sackler School of Medicine, Tel Aviv University
- 2008 Visiting Professor, Department of Health Policy and Management, Mailman School of Public Health, Columbia University
- 2009 Visiting Professor, Department of Health Policy and Management, Mailman School of Public Health, Columbia University

**D. COORDINATION OF CLINICAL TRIALS**

- 1986 - 1989 Principal investigator & Chief Coordinator of the “Israeli Study of Early Intervention in Acute Myocardial Infarction”, involving the Tel Aviv and Sheba Medical Centers. Operating Budget - 750,000 DM
- 1989 - 1990 National Coordinator and principal investigator of the International rt-PA/STK Mortality Trial (**GISSI- II**) involving all the intensive coronary care units in Israel. Operating Budget - \$650,000
- 1991 - 1993 National Coordinator and principal investigator of the **GUSTO-I** Study (an FDA audited trial) of thrombolytic therapy in AMI involving all the intensive coronary care units in Israel. Operating Budget - \$1,200,000
- 1994 - 1995 National Coordinator and principal investigator of the **TIMI-9** Study, Hirudin versus Heparin, (an FDA audited trial) in AMI involving all the intensive coronary care units in Israel. Operating Budget - \$860,000.
- 1997 - 1998 National Coordinator and principal investigator of the **ASSENT II** Study, Thrombolytic Therapy trial, (an FDA audited trial) in AMI

involving all the intensive coronary care units in Israel. Operating Budget - over \$3,000,000.

**E. CLINICAL & ADMINISTRATIVE EXPERIENCE**

- 1976 – 1978 Flight Surgeon, Israeli Air Force
- 1978 – 1979 Deputy Surgeon General, Israeli Air Force
- 1980 – 1983 Coordinator of the Emergency Medical Services  
Israel International “Ben-Gurion” Airport
- 1980 – 1984 Physician of the Combined Air-ground Operations’ Command.  
Israeli Air Force
- 1986 – 1990 Deputy Director  
The Sheba Medical Center, Israel
- 1990 – 1993 Deputy Director of the Sheba Medical Center and  
Director of the Rehabilitation Hospital  
The Sheba Medical Center, Israel
- 1993 – 1996 Director General, The Tel-Aviv Sourasky Medical Center
- 1995 – 1998 Member of the Scientific Committee of the Interdisciplinary Center  
for Technological Analysis and Forecasting at Tel-Aviv University
- 1996 – 1999 Director General, (Surgeon General) The Ministry of Health.
- 1998 – 2000 Chairman, Israeli National Transplant Center
- 1999 - Director General, The Tel-Aviv Sourasky Medical Center

**F. ACADEMIC AND PROFESSIONAL AWARDS**

- 1984 - 1985 Kellogg Fellow in Health Services Administration, Kellogg Foundation

**G. ACTIVE PARTICIPATION IN SCIENTIFIC MEETINGS**

1. **Barbash GI**, Bar-Meir S, Bar-Shani, S, & Gilon O. The prevalence of elevated serum alanin amino transferase among blood donors in Israel and its significance. 12<sup>th</sup> Congress of the Israel Medical Association 1982
2. **Barbash GI**, Hod H, Roth A, Rath S, Har-Zahav Y, Rabinowitz B, & Seligsohn U. Cycles of reocclusion-reperfusion during rt-PA treatment in

patients with acute myocardial infarction. Presented at the Thrombosis and Hemostasis conference, Brussels, July 1987

3. **Barbash GI**, Hod H, Miller HI, Roth A, Rath S, Har-Zahav Y, Rabinowitz B, Laniado S, & Seligsohn U. The Israeli study of early intervention in myocardial infarction; intravenous rt-PA with subsequent mechanical revascularization. Presented at the Thrombosis and Hemostasis conference, Brussels, July 1987
4. Roth A, **Barbash GI**, Hod H, Miller HI, Keren G, Laniado S, & Seligsohn U. Bleeding complications during rt-PA thrombolysis related to use of anti-inflammatory drugs prior to acute myocardial infarction admission. Presented at the Thrombosis and Hemostasis conference, Brussels, July 1987
5. **Barbash GI**. Early administration of intravenous rt-PA thrombolysis in acute myocardial infarction. Combination of pre-hospital with hospital treatment. Presented in the symposium on “Principles and advances in thrombolytic therapy” in the fifth joint meeting of the European Society of Cardiology, Spain, September 1987
6. **Barbash GI**, Hod H, Rath S, Roth A, Miller HI, Modan M, Seligsohn U, Rabinowitz B, Laniado S. The Israeli study of early intervention in myocardial infarction; intravenous rt-PA with delayed mechanical revascularization. Preliminary results. Presented in the American Heart Association Meeting, Anaheim, November 1987
7. **Barbash GI**, Hod H, Rath S, Seligsohn U, Battler A, Har-Zahav Y, Modan M, Rabinowitz B. Intermittent, dose-related reocclusion during infusion of recombinant tissue plasminogen activator in myocardial infarction patients. Presented in the American Heart Association Meeting, Anaheim, November 1987
8. Roth A, **Barbash GI**, Hod H, Miller HI, Rath S, Modan M, Behar S, Rabinowitz B, Laniado S. Effectiveness and safety of intravenous tissue plasminogen activator thrombolysis by mobile intensive care units in acute myocardial infarction. Presented in the American College of Cardiology Meeting, Atlanta, March 1988
9. **Barbash GI**, Hod H, Roth A, Miller HI, Rath S, Har-Zahav Y, Agranat O, Modan M, Rabinowitz B, Laniado S, Seligsohn U. Association between fibrinolytic parameters and coronary patency in AMI patients treated with rt-PA thrombolysis. Presented in the American Heart Association Meeting, Washington, November 1988
10. **Barbash GI**, Roth A, Hod H, Rath S, Miller HI, Kuznitz F, Har-Zahav Y, Agranat O, Modan M, Motro M, Keren G, Battler A, Kaplinsky E, Rabinowitz B, Laniado S. Significance of rapid ST-resolution to predict short and long-term outcome of AMI patients undergoing rt-PA thrombolysis. Presented in the American Heart Association Meeting, Washington, November 1988

11. **Barbash GI**, Hod H, Roth A, Modan M, Miller HI, Rath S, Har-Zahav Y, Agranat O, Keren G, Motro M, Shachar A, Basan S, Rabinowitz B, Laniado S, Kaplinsky E. Randomized controlled trial of late in-hospital angiography and angioplasty vs. conservative management after rt-PA treatment in acute myocardial infarction. Presented in the American College of Cardiology Meeting, New Orleans, March 1990
12. **Barbash GI**. Results of the GISSI and International t-PA/STK Trial. Annual Meeting of Spanish National Association of Cardiology, Madrid, May 1990
13. **Barbash GI**. Discussion of the results of international trials in thrombolytic therapy of cardiovascular diseases. Meeting of the National Italian Association of Pharmaco-therapy Cardiologists, Padua, May 1990
14. **Barbash GI**. Pre-hospital administration of thrombolytic therapy. Annual Meeting of the Italian National Association of Hospital Cardiologists, Bologna, June 1990
15. **Barbash GI**, Eisenberg MJ, Hod H, Roth A, Shachar A, Modan M, Zolti L, Kaplinsky E, Laniado S, Rabinowitz B. The prognostic importance of late Q-wave development following thrombolytic therapy for acute myocardial infarction. Presented in the American College of Cardiology Meeting, Atlanta, March 1991
16. Matetzky S, **Barbash GI**, Shahar A, Rabinowitz B, Rath S, Har-Zahav Y, Agranat O, Kaplinsky E, Hod H. The prognostic significance of early inversion T-waves after thrombolytic therapy for acute myocardial infarction. Presented in the American Heart Association Meeting, Anaheim, November 1991
17. **Barbash GI**, White H, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Mouloupoulos S, Paolasso EAC, Pehrsson K, Sandoe E, Simes J, Wilcox RG, Verstraete M, Von der Lippe G, Van der Werf T, Van de Werf F. Pre-infarction angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy - experience gathered in the International TPA/STK Trial. Presented in the American College of Cardiology Meeting, Dallas, April 1992
18. **Barbash GI**, Goldbourt U, Modan M, White H, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Mouloupoulos S, Paolasso EAC, Pehrsson K, Sandoe E, Simes J, Wilcox RG, Verstraete M, Von der Lippe G, Van de Werf F. Comparative mortality analysis of the International TPA/STK Trial. An unexplained variance. Presented in the American College of Cardiology Meeting, Dallas, April 1992
19. **Barbash GI**. Rescue thrombolysis. Presented in the International Symposium on Update in Thrombolysis, Hannover, October 1992
20. **Barbash GI**, White H, Modan M, Van de Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Presented in the American College of Cardiology Meeting, Anaheim, March 1993

21. Gottlieb S, **Barbash GI**, Khoury Z, Behar S, on behalf of the Israeli Thrombolytic Study Group. Effect of advanced age on use of thrombolytic therapy and mortality in acute myocardial infarction. Presented in the European Cardiology Society Meeting, Nice, France, September 1993.
22. **Barbash GI**, for the Israeli investigators. Rescue thrombolysis in reinfarction. Presented in the American Heart Association Meeting, Anaheim, November 1993.
23. Col J, White HD, Aylward P, **Barbash GI**, for the GUSTO Trial Investigators. Effects of intravenous versus subcutaneous heparin as adjunctive therapy to streptokinase: Results of the GUSTO Trial. Presented in the Am Heart Association Meeting, Anaheim, November 1993.
24. White HD, **Barbash GI**, Modan M, Simes J, Van de-Werf F, for the investigators of the International Mortality Trial. After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men, except for a higher incidence of hemorrhagic stroke. Presented in the Am Heart Association Meeting, Anaheim, November 1993.
25. Behar S, **Barbash GI**, Goldbourt U, and the SPRINT and Thrombolytic Study Groups. Have changes in the management of acute myocardial infarction between the 80's and 90's reduced mortality? Presented in the Am Heart Association Meeting, Anaheim, November 1993.
26. Behar S, **Barbash GI**, for the Israeli Thrombolytic Study Groups. Group use of coronary procedures in patients with acute myocardial infarction hospitalized in centers with and without coronary angiography facilities in Israel. Presented in the American College of Cardiology Meeting, Atlanta, March 1994.
27. **Barbash GI**, White HD, Gore JM, Granger C, Weaver WD, Simoons ML, Aylward P, Van de Werf F, for the GUSTO Trial Investigators. More aggressive thrombolytic treatment increases stroke risk: results from the GUSTO trial. Presented in the American College of Cardiology Meeting, Atlanta, March 1994.
28. Gore JM, **Barbash GI**, White HD, Granger C, Weaver WD, Simoons ML, Aylward P, Van de Werf F, for the GUSTO Trial. Functional status following stroke after thrombolytic therapy-results from the GUSTO trial. Presented in the American College of Cardiology Meeting, Atlanta, March 1994.
29. **Barbash GI**, Ohman EM, White HD, Granger C, Califf RM, for the GUSTO Investigators. Rescue thrombolysis for suspected reinfarction following thrombolytic therapy: experience from the GUSTO trial. Presented in the American College of Cardiology Meeting, Atlanta, March 1994.
30. Behar S, **Barbash GI**, for the Israeli Thrombolytic Survey Group. Use of coronary procedures in patients with acute myocardial infarction hospitalized in centers with and without coronary angiography facilities in Israel. Presented in the American College of Cardiology Meeting, Atlanta, March 1994.

31. **Barbash GI**, Reiner JS, Granger CB, White HD, Lundergan CF, Ross AM, for the GUSTO Investigators. Smoking and Acute Myocardial Infarction Survival: Demographic and Quantitative Angiographic Foundations for the "Smoker's Paradox". Presented in the American Heart Association Meeting, Dallas, November 1994.
32. Gottlieb S, Goldbourt U, **Barbash GI**, Boyko V, Behar S, the SPRINT and the Israeli Thrombolytic Survey Group. The Prognosis of Elderly ( $\geq 75$ ) Patients Hospitalized With Acute Myocardial Infarction From 1981-83 to 1992 in Israel. Presented in the American Heart Association Meeting, Dallas, November 1994.
33. White HD, Granger C, Gore J, **Barbash GI**, for the GUSTO Investigators. Older Age is Associated With a Large Increase in Mortality and Total Stroke, but Not Non-fatal Disabling Stroke: Results of the GUSTO trial. Presented in the American Heart Association Meeting, Dallas, November 1994.

#### **H. MEMBERSHIP IN PROFESSIONAL SOCIETIES**

1. Israeli Medical Association
2. Israeli Cardiology Association
3. Israeli Association of Hospital Directors

#### **H. 1.**

4. Editorial Board - The Journal of Thrombosis and Thrombolysis

#### **I. M.D. STUDENTS SUPERVISED BY CANDIDATE**

- 1990 Zack Ben Naim; Correlation of meteorological parameters and incidence of acute myocardial infarction. The Sheba Medical Center, Israel
- 1990 Suzana Feldman; Prognostic importance of clinical characteristic of prior AMI in patients with AMI receiving thrombolytic therapy

### **LIST OF SCIENTIFIC PUBLICATIONS**

#### **B.1. ORIGINAL ARTICLES**

##### **PUBLISHED ARTICLES**

1. Noyman Y, Hornung S, **Barbash GI**, & Margalio S. Medical air-evacuation during the Lebanon War 1982. Israel J Med Scien 1984; 20:303-305
2. Bar-Meir S, Bar-Shani S, & **Barbash GI**. Significance of elevated serum alanin amino transferase in Israeli blood donors. Israel J Med Scien 1984; 20:1112-1114
3. **Barbash GI**, Yoeli N, Ruskin S, & Moeller DW. Airport preparedness for mass disaster; a proposed schematic plan. Aviat Space Envriom Med 1986; 57:77-81

4. **Barbash GI**, Rabkin MT, Kane NM, & Baim DS. Coronary angioplasty under the prospective payment system: the need for a severity-adjusted payment scheme. *J Am Coll Cardiol* 1986; 8(4):784-790
5. **Barbash GI**, Safran C, Ransil BJ, Pollack RA, & Pasternak RC. Need for better severity indexes of acute myocardial infarction under diagnosis-related groups. *Am J Cardiol* 1987; 59:1052-1056
6. **Barbash GI**, Laniado S. Coronary angioplasty in Israel - budgetary perspectives. *Harefuah* 1987; 112(11):566-568
7. **Barbash GI**, Ribak J, Revah M, Swedenburg M, Dolev E. Management control of aeromedical evacuation. *Aviat Space Environ Med* 1988; 59:172-5
8. **Barbash GI**, Hod H, Rath S, Miller HI, Roth A, Har-Zahav Y, Modan M, Rotstein Z, Battler A, Zivelin A, Charnilass J, Laniado S, Kaplinsky E, Rabinowitz B, Seligsohn U. Intermittent, dose-related reocclusion-reperfusion cycles during infusion of recombinant tissue plasminogen activator in myocardial infarction patients. *Am J Cardiol* 1989; 64:225-228
9. **Barbash GI**, Hod H, Roth A, Miller HI, Rath S, Har-Zahav Y, Modan M, Zivelin A, Laniado S, Kaplinsky E, Seligsohn U. Correlation of baseline plasminogen inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. *Am J Cardiol* 1989; 64:1231-5
10. **Barbash GI**. Thrombolytic therapy in acute coronary artery diseases. Part A. *Harefuah* 1989; 116:152-8
11. **Barbash GI**. Thrombolytic therapy in acute coronary artery diseases. Part B. *Harefuah* 1989; 116:210-213
12. Roth A, **Barbash GI**, Hod H, Miller HI, Rath S, Modan M, Har-Zahav Y, Keren G, Bassan S, Kaplinsky E, Laniado S. Should rt-PA be administered in the mobile intensive care unit in patients with evolving myocardial infarction. *J Am Coll Cardiol* 1990; 15:932-6
13. Roth A, Miller HI, Kaluski E, Keren G, Shargorodsky B, Krakover R, **Barbash GI**, Laniado S. Early thrombolytic therapy does not enhance the recovery of the right ventricle in patients with acute inferior myocardial infarction and predominant right ventricular involvement. *Cardiology* 1990; 77:40-49
14. **Barbash GI**, Hod H, Faibel HE, Ziskind Z, Agranat O, Hirsh R, Schlezinger Z, Smolinsky A. Continuous rt-PA infusion as a salvage strategy to maintain patency of the infarct artery; safety of high cumulative dose and subsequent emergency coronary artery angioplasty and bypass surgery. *Biomed & Pharmacother* 1990; 44:185-9
15. **Barbash GI** and other collaborators of the International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase or streptokinase with or without heparin. *Lancet* 1990; ii:71-75.



16. Strasberg B, Pinchas A, **Barbash GI**, Hod H, Rath S, Har-Zahav Y, Caspi A, Sclarovsky S, Agmon J. Importance of reciprocal ST segment depression in leads V<sub>5</sub> and V<sub>6</sub> as a indicator of disease of the left anterior descending coronary artery disease in acute inferior wall myocardial infarction. *Br Heart J* 1990; 63:339-41
17. **Barbash GI**, Roth A, Hod H, Miller HI, Modan M, Rath S, Har-Zahav Y, Shachar A, Basan S, Battler A, Rabinowitz B, Kaplinsky E, Seligsohn U, Laniado. Improved survival but not left ventricular function with early and pre-hospital treatment with tissue plasminogen activator in patients with acute myocardial infarction. *Am J Cardiol* 1990; 66:261-6
18. **Barbash GI**, Hod H, Roth A, Modan M, Miller HI, Rath S, Har-Zahav Y, Keren G, Motro M, Shachar A, Basan S, Rabinowitz B, Laniado S, Kaplinsky E. Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction. *Am J Cardiol* 1990; 66:538-45
19. **Barbash GI**, Hod H, Roth A, Faibel HE, Mandel Y, Miller HI, Rath S, Har-Zahav Y, Rabinowitz B, Seligsohn U, Pelled B, Schlesinger Z, Motro M, Laniado S, Kaplinsky S. Repeated infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia. *J Am Coll Cardiol* 1990; 16:779-83
20. **Barbash GI**, Roth A, Hod H, Miller HI, Rath S, Har-Zahav Y, Modan M, Seligsohn U, Battler A, Kaplinsky E, Rabinowitz B, Laniado S. Rapid resolution of ST elevation and prediction of clinical outcome of patients undergoing thrombolysis with recombinant tissue-type plasminogen activator: results of the Israeli study of early intervention in myocardial infarction. *Br Heart J* 1990; 64:241-7
21. Hornik J, Zaig T, Shadmon D, **Barbash GI**. Comparison of three inducement techniques to improve compliance in a health survey conducted by telephone. *Public Health Reports* 1990; 105:524-9
22. Eizenberg MJ, **Barbash GI**, Hod H, Roth A, Shacher A, Zolti L, Rabinowitz B, Kaplinsky E, Laniado S, Modan M. Prognostic importance of delayed Q-wave evolution 3 to 24 hours after initiation of thrombolytic therapy for acute myocardial infarction. *Am J Cardiol* 1991; 67:231-5
23. Behar S, Hod H, **Barbash GI**, Kaplinsky E. Incidence of and reasons for excluding patients with acute myocardial infarction from thrombolytic therapy. *Isr J Med Sci* 1991; 27:121-3
24. Motro M, **Barbash GI**, Hod H, Roth A, Kaplinsky E, Laniado S, Keren G. Incidence of left ventricular thrombi formation after thrombolytic therapy with recombinant tissue plasminogen activator, heparin and aspirin in patients with acute myocardial infarction. *Am Heart J* 1991; 122:23
25. **Barbash GI**, White HD, Modan M, Van de Werf F. Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International TPA/STK Trial. *J Am Coll Cardiol* 1992; 20:36-41

26. Topol EJ, Armstrong P, Van de Werf F, Kleiman N, Lee K, Morris D, Simoons M, **Barbash GI**, White H, Califf RM. Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. *J Am Coll Cardiol* 1992; 19:1123-8
27. Shechter M, Rabinowitz B, Beker B, Motro M, **Barbash GI**, Kaplinsky E, Hod H. Additional ST-segment elevation during the first hour of thrombolytic therapy: an electrocardiographic sign predicting a favorable clinical outcome. *J Am Coll Cardiol* 1992; 20:1460-4
28. **Barbash GI**, White H, Modan M, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Mouloupoulos S, Paolasso EAC, Pehrsson K, Sandoe E, Simes J, Wilcox RG, Verstraete M, Von der Lippe G, Van der Werf T, Van de Werf F. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. *Circulation* 1993; 87:53-58
29. **Barbash GI**, Modan M, Goldbourt U, White H, Van de Werf F. Comparative case fatality analysis of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Variation by country beyond predictive profile. *J Am Coll Cardiol* 1993; 21:281-6.
30. Roth A, Miller HI, Glick A, **Barbash GI**, Laniado S. Rapid resolution of new right bundle branch block in acute anterior myocardial infarction patients after thrombolytic therapy. *Pace* 1993; 16:13-18.
31. **Barbash GI**, White H, Modan M, Van de Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. *J Am Coll Cardiol*, 1993;22:707-13
32. GUSTO Investigators (**Barbash GI**, National Coordinator for the State of Israel and member of the International Steering Committee). An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl J Med*, 1993;329:673-82
33. White H, **Barbash GI**, Modan M, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Mouloupoulos S, Paolasso EAC, Pehrsson K, Sandoe E, Simes J, Wilcox RG, Verstraete M, Von der Lippe G, Van der Werf T, Van De Werf F. After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. *Circulation*, 1993;88:2097-2103
34. Behar S, Hod H, Narinsky R, Benari B, Rechavia E, Pazner H, Rougin N, Karkover O, Katz A, Roth A, Goldhammer E, Rudnic L, Faibel HE, Lotan C, Shapira H, Jafari J, Frieberg N, Daka F, Kanetti M, Gottlieb S, Weiss T, Barash E, Gluckstein M, Blondheim D, Mahul N, Gelvan A, **Barbash GI**. Influence of gender in the therapeutic management of patients with acute myocardial infarction in Israel. The Israeli Thrombolytic Survey. *Am J Cardiol*, 1994;73:438-443
35. Matetzky S, **Barbash GI**, Shahar A, Rabinowitz B, Rath S, Har-Zahav Y, Agron O, Kaplinsky E. Early T-wave inversion after thrombolytic therapy predicts better coronary perfusion: clinical and angiographic study. *J Am Coll Cardiol*, 1994;24:378-83

36. **Barbash GI**, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Mouloupoulos S, Paolasso EAC, Van der Werf T, Pehrsson K, Sandoe E, Simes J, Wilcox RG, Verstraete M, Von der Lippe G, Van der Werf F for the Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Outcome of Thrombolytic Therapy in Relation to Hospital Size and Invasive Cardiac Services. *Annal. Int Med*, 1994;154:2237-42
37. Shahar A, Hod H, **Barbash GI**, Kaplinsky E, Motro M. Disappearance of a Syndrome: Dressler's Syndrome in the Era of Thrombolysis. *Cardiology* 1994;85:255-8
38. Behar S, **Barbash GI**, Copel L, Goldcourt U, for the SPRINT study group. Improved survival of hospitalized patients with acute myocardial infarction from 1981-3 to 1992 in Israel. *Coron Art Dis*. 1994;5:1001-7
39. **Barbash GI**, White HD, Modan M, Diaz R, Hampton JR, Heikkila, Kristinsson A, Mouloupoulos S, Ernesto AC, Van der Werf T, Pehrsson K, Sandoe E, Simes J, Wilcox G, Verstraete M, Von der Lippe G, Van de Werf F. Acute Myocardial Infarction in the Young - The Role of Smoking. *Europ. Heart J*. 1995;16:313-6.
40. Van de Werf F, Topol EJ, Lee KL, Woodlief LH, Granger CB, Armstrong PW, **Barbash GI**, Hampton JR, Guerci A, Simes RJ, Ross AM, Califf RM. Variations in patient management and outcomes for Acute Myocardial Infarction in the United States and Other Countries. Results from the GUSTO Trial. *JAMA* 1995;273:1586-1591
41. Behar S, Hod H, Benari B, Narinsky R, Pazner H, Rechavia E, Faibel HE, Katz A, Roth A, Goldhammer E, Freedberg NA, Rougin N, Kracoff O, Shapira C, Jafari J, Lotan C, Daka F, Gottlieb S, Weiss T, Kanetti M, Klutstein M, Rudnik L, Barasch E, Mahul N, Blondheim D, Gelvan A, **Barbash GI**, for the Israeli Thrombolytic Survey Group. On-Site Catheterization Laboratory and Prognosis after Acute Myocardial Infarction. *Arch. Int. Med*. 1995;155:813-7
42. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, **Barbash GI**, White H, Simoons ML, Nelson CL, Clapp-Channing N, Knight JD, Harrell FE, Simes J, Topol EJ. Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator As Compared With Streptokinase for Acute Myocardial Infarction. *N Eng J Med*. 1995; 332:1418-24
43. Gottlieb S, Goldbourt U, Boyko V, **Barbash GI**, Mandelzweig L, Behar S, for the SPRINT and Thrombolytic Survey groups. Improvement in the Prognosis of Patients With Acute Myocardial Infarction in the 1990s Compared With the Prethrombolytic Era: An Analysis by Age Subgroups. *Am J Ger Card*, 1995;4 No.6:17-31
44. **Barbash GI**, Reiner J, White HD, Wilcox RG, Armstrong PW, Sadowski Z, Morris D, Aylward P, Woodlief RG, Topol EJ, Califf RM, Ross AM for the GUSTO Investigators. Evaluation of the Paradoxical Beneficial Effects of Smoking in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction; Mechanism of the "Smoker's Paradox" from the GUSTO Trial, with Angiographic Insights. *J Am Coll Cardiol*, 1995;26:1222-9

45. Gore JM, Granger CB, Sloan MA, Van de Werf F, Weaver WD, Califf RM, White HD, **Barbash GI**, Simoons ML, Aylward PE, Topol EJ. Stroke after Thrombolysis: Mortality and Functional Outcomes in the GUSTO-I Trial. *J. Am Heart A*, 1995;2811-2818.
46. Behar S, Goldbourt U, **Barbash GI**, Modan B, for the SPRINT study group. Twenty five year mortality rate decrease in patients with a first episode of acute myocardial infarction. *Am Heart J*. 1995, 130:453-8
47. Birnbaum Y, Herz I, Sclarovsky S, Zlotikamien B, Chetrit A, Olmer L, **Barbash GI**. Prognostic Significance of the Admission Electrocardiogram in Acute Myocardial Infarction. *J Am Coll Cardiol*, 1996;27:1128-32.
48. Rotstein Z, **Barbash GI**, Goldman B, Chetrit A, Modan M, Shani M, Noy S. Allocation of emergency ward patients to medicine departments: increasing physicians' incentive to shorten length-of-stay. *Public Health Reviews*, 1996;24:37-48.
49. Birnbaum Y, Herz I, Sclarovsky S, Zlotikamien B, Chetrit A, Olmer L, **Barbash GI**. Prognostic Significance of Precordial St-segment Depression on Admission Electrocardiogram in Patients With Inferior Wall Myocardial Infarction. *J Am Coll Cardiol*, 1996;28:313-8.
50. Weaver WD, White HD, Wilcox RG, Aylward PE, Guerci A, Morris DC, Ohman EM, **Barbash GI**, Betriu A, Sadowski Z, Topol EJ, Califf RM, for the GUSTO-I Investigators. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. *JAMA* 1996;275:777-782.
51. Behar S, Gottlieb S, Hod H, Benari B, Narinsky R, Pauzner H, Rechavia E, Faibel H, Katz A, Roth A, Goldhammer E, Freedberg NA, Rougin N, Kracoff O, Shapira C, Jafari J, Lotan C, Daka F, Weiss T, Kanetti M, Klutstein M, Rudnik L, Barasch E, Mahul N, Blondheim D, Gelvan A, and **Barbash GI**. The Outcome of Patients with Acute Myocardial Infarction Ineligible for Thrombolytic Therapy". *Am J Med*, 1996;101:184-91
52. Kornowski R, Chetrit A, **Barbash GI**. Prognostic Importance of Previous Myocardial Infarction in Patients Receiving Thrombolytic Therapy for Acute Infarction. *J of Thrombosis and Thrombolysis*, 1996;3:391-395
53. Antman EM, for the TIMI 9B Investigators (**Barbash GI**, National Coordinator for the State of Israel and member of the International Steering Committee). Hirudin in Acute Myocardial Infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. *Circulation*, 1996;94 No 5: 911-921
54. White HD, **Barbash GI**, Califf RM, Simes JR, Granger CB, Weaver WD, Kleiman NS, Aylward PE, Gore JM, Vahanian A, Lee KL, Ross AM, Topol EJ. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I Trial. *Circulation*, 1996; 94: 1826-33.
55. Gottlieb S, Goldbourt U, Boyko V, **Barbash GI**, Mandelzweig L, Behar S, for the SPRINT and Thrombolytic Survey Groups. Improved Outcome of Elderly

- Patients  $\geq$  75 years With Acute Myocardial Infarction From 1981-83 to 1992-4 in Israel. *Circulation*, 1997; 95: 342-50.
56. Birnbaum Y, Chetrit A, Sclarovsky S, Zlotikamien B, Herz I, Olmer L, **Barbash GI**. Abnormal Q waves on the admission electrocardiogram of patients with first acute myocardial infarction: prognostic implications. *Clin Cardiol*, 1997; 20: 477-81.
  57. Birnbaum Y, Sclarovsky S, Herz I, Zlotikamien B, Chetrit A, Olmer LB, **Barbash GI**. Admission Clinical and Electrocardiographic Characteristics Predicting In-Hospital Development of High Degree Atrio-Ventricular Block in Inferior Wall Acute Myocardial Infarction. *Am. J. Cardiol*, 1997; 80: 1134-38.
  58. Califf RM, Woodlief LH, Lee KL, Harrell FE Jr., White HD, Guerci A, **Barbash GI**, Simes JR, Weaver WD, Topol EJ, for the GUSTO -I Investigators. Selection of Thrombolytic Therapy for Individual Patients: Development of a Clinical Model. *Am H.J.* 1997;133:630-9.
  59. Mahaffey KW, Granger CB, Toth C, White HD, Stebbins AL, **Barbash GI**, Vahanian A, Topol EJ, Califf RM. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. *J Am Coll Cardiol.* 1997; 30(7): 1606-10
  60. Mahaffey KW, Granger CB, Sloan MA, Thompson TD, Gore JM, Weaver WD, White HD, Simoons ML, **Barbash GI**, Topol EJ, Califf RM, for the GUSTO-I Investigators. Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. *Circulation.* 1998 Mar 3; 97(8): 757-64
  61. Birnbaum Y, Herz I, Sclarovsky S, Zlotikamien B, Chetrit A, Olmer L, **Barbash GI**. Admission Clinical and Electrocardiographic Characteristics Predicting an Increased Risk for Early Reinfarction After Thrombolytic Therapy. *Am. H.J.* 1998;135: 805-12
  62. Barbash IM, Halperin P, Rot A, Hod H, **Barbash GI**. Comparison of Baseline Characteristics and Outcome of Patients with Chest Pain Brought to the Hospital by Private versus Public Intensive Care Units. *J. Thrombosis & Thrombolytic* 1998;6:207 - 209
  63. Birnbaum Y, Wagner GS, **Barbash GI**, Gates K, Criger DA, Sclarovsky S, Siegel RJ, Granger CB, Reiner JS, Ross AM. Correlation of Angiographic Findings and Right (V<sub>1</sub> to V<sub>3</sub>) Versus Left (V<sub>4</sub> to V<sub>6</sub>) Precordial ST-segment Depression in Inferior-wall Acute Myocardial Infarction. *Am. J. Cardiol* 1999;83(2):143-8
  64. ASSENT-II Investigators (**Barbash GI**, Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-II) Investigators). Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-II double-blind randomized trial. *Lancet* 1999;354:716-722
  65. Herz I, Birnbaum Y, Zlotikamien B, Strasberg B, Sclarovsky S, Chetrit A, Wagner GS, **Barbash GI**. The prognostic implications of Negative T waves

- in the Leads with ST Segment Elevation on Admission in Acute Myocardial Infarction. *Cardiology* 1999;92(2):121-127
66. Mahaffey KW, Granger CB, Sloan MA, Green CL, Gore JM, Weaver WD, White HD, Simoons ML, **Barbash GI**, Topol EJ, Califf RM. Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. *Am Heart J* 1999;138:493-9
  67. Birnbaum Y, Wagner GS, Gates KB, Thompson TD, **Barbash GI**, Siegel RJ, Granger CB, Fishbein MC, Crenshaw BS, Califf RM. Clinical and Electrocardiographic Variables Associated with Increased Risk of Ventricular Septal Defect in Acute Anterior Myocardial Infarction. *Am. J. Cardiol* 2000;86:830-834
  68. **Barbash GI**, Birbaum Y, Bogaerts K, Hudson M, Lesaffre E, Fu Y, Goodman S, Houbracken K, Munsters K, Granger CB, Pieper K, Califf RM, Topol EJ, Van de Werf F. Treatment of Reinfarction After Thrombolytic Therapy for Acute Myocardial Infarction: An Analysis of Outcome and Treatment Choices in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO I) and Assessment of the Safety of a New Thrombolytic (ASSENT 2) Studies. *Circulation* 2001;103:954-960.
  69. Birnbaum Y, Criger DA, Strasberg B, Mager A, Wagner GS, Gates KB, Granger CB, Ross AM, **Barbash GI**. Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram. *Am. Heart J* 2001 Jun;141(6):915-924.
  70. Birnbaum Y, Goodman S, Barr A, Gates KB, **Barbash GI**, Battler A, Barbagelata A, Clemmensen P, Sgarbossa EB, Granger CB, Califf RM, Wagner GS. Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. *Am. J. Cardiol* 2001;88:842-47.
  71. Hudson MP, Granger CB, Topol EJ, Pieper KS, Armstrong PW, **Barbash GI**, Guerci AD, Vahanian A, Califf RM, Ohman EM. Early Reinfarction after Fibrinolysis: Experience from the GUSTO-I and GUSTO-III Trials. *Circulation* 2001;104(11):1229-35
  72. Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S.O., **Barbash GI**, Pehrsson K, Verheugt FWA, Meyer J, Betriu A, Califf RM, Li X, Fox NL, for the ASSENT-2 Investigators. Incidence and Predictors of Bleeding Events After Fibrinolytic Therapy with Fibrin-Specific Agents: A Comparison of TNK-tPA and rt-PA. *European Heart J.* 2001;24:2253-61
  73. Birnbaum Y, Mahaffey KW, Criger DA, Gates KB, **Barbash GI**, Barbagelata A, Clemmensen P, Sgarbossa EB, Gibbons RJ, Califf RM, Granger CB, Wagner GS for the AMISTAD Investigators. Grade III Ischemia on Presentation in Acute Myocardial Infarction Predicts Rapid Progression of Necrosis and Less Myocardial Salvage with Thrombolytic Therapy. *Cardiology* 2002;97:166-174

74. Gupta M, Chang WC, Van de Werf F, Granger CB, Midodzi W, **Barbash GI**, Pehrson K, Oto A, Toutouzas P, Jansky P, Armstrong PW for the ASSENT II Investigators. International Differences in In-Hospital Revascularization and Outcomes Following Acute Myocardial Infarction: A Multilevel Analysis of Patients in ASSENT-II. *European Heart J.* 2003;24:1640-1650
75. Schreiber S, Yoeli N, Paz G, Barbash GI, Verssano D, Fertel N, Hassner A, Drory M, Halpern P. Hospital Preparedness for Possible Nonconventional Casualties: an Israeli Experience. *Gen Hospital Psychiatry*, 2004;26(5):359-66
76. Barbash GI, Glied S. New Health Care Technologies and Health Care Costs: The Case of Robot-Assisted Surgery, *N Eng J Med* 2010; 363;8: 701-704
77. Barbash GI, Friedman B, Glied SA, Steiner CA. Factors associated with adoption of robotic surgical technology in US hospitals and relationship to radical prostatectomy procedure volume. *Annals of Surgery*, 2013,259:1;1-6  
doi: 10.1097/SLA.0b013e3182a5c8b8  
[http://journals.lww.com/annalsofsurgery/Abstract/publishahead/Factors\\_Associated\\_With\\_Adoption\\_of\\_Robotic.98372.aspx](http://journals.lww.com/annalsofsurgery/Abstract/publishahead/Factors_Associated_With_Adoption_of_Robotic.98372.aspx)

### Accepted Articles

1. Bernard Friedman PhD, Gabriel I. Barbash, MD, MPH, Sherry A. Glied, PhD, Claudia A. Steiner, MD, MPH. Hospital Revisits within 30 Days after Robotically-Assisted Hysterectomy. *Medical Care*

### Submitted Articles

#### B.2. CASE REPORTS

1. Weinberger A, Benjamin D, Douer D, **Barbash GI**, Djaldetti M, and Pinkhas J. A 13 years remission in chronic myelocytic leukemia after a single course of Busulfan. *Acta Haemat* 1978; 59:354-359
2. **Barbash GI**, Solomon A, Reider Grosswasser I, Vidne BA, and Almog C. Aortic dissection presenting with hemoptysis: diagnostic confirmation of dissection and leak by computerized tomography. *Heart & Lung J* 1983; 12:633-635
3. **Barbash GI**, Keren G, Korczyn AD, Sharpless NS, Chayn M, Kuperman Y, and Laniado S. Mechanism of syncope - glossopharyngeal neuralgia. *J Electroenceph & Clinic Neurophysiology* 1986; 63:231-235

#### D. CHAPTER IN BOOK

1. **Barbash GI**. Time dependence of beneficial effects of thrombolysis and pre-hospital thrombolytic therapy in acute myocardial infarction. In: *Thrombolysis in Cardiovascular Diseases*. Julian D, Kubler W, Norris RM, Swan HJC, Collen D, Verstraete M, eds., by Marcel Dekker Inc 1989, pp293-308

**E.1. & 2. PAPERS PRESENTED AT SCIENTIFIC MEETINGS**

1. Korczyn AD, **Barbash GI**, Keren G, Chayen M, Sharpless NS, Cooperman Y, Laniado S. Mechanisms of syncope in glossopharyngeal neuralgia. *Electroenceph & Clinic Neurophysiology* 1985; 67:35
2. **Barbash GI**, Hod H, Roth A, Rath S, Har-Zahav Y, Rabinowitz B, & Seligsohn U. Cycles of reocclusion-reperfusion during rt-PA treatment in patients with acute myocardial infarction. *Thrombosis & Hemostasis* 1987; 58(1):177A
3. Roth A, **Barbash GI**, Hod H, Miller HI, Keren G, Laniado S, & Seligsohn U. Bleeding complications during rt-PA thrombolysis related to use of anti-inflammatory drugs prior to acute myocardial infarction admission. *Thrombosis & Hemostasis* 1987; 58(1):178A
4. **Barbash GI**, Hod H, Miller HI, Roth A, Rath S, Har-Zahav Y, Rabinowitz B, Laniado S, & Seligsohn U. The Israeli study of early intervention in myocardial infarction: intravenous rt-PA with subsequent mechanical revascularization. *Thrombosis & Hemostasis* 1987; 58(1):946A
5. **Barbash GI**, Hod H, Rath S, Roth A, Miller HI, Modan M, Seligsohn U, Rabinowitz B, Laniado S. The Israeli study of early intervention in myocardial infarction: intravenous rt-PA with delayed mechanical revascularization. Preliminary results. *Circulation* 1987; 76(4):1211A
6. **Barbash GI**, Hod H, Rath S, Seligsohn U, Battler A, Har-Zahav Y, Modan M, Rabinowitz B. Intermittent, dose-related reocclusion during infusion of recombinant tissue plasminogen activator in myocardial infarction patients. *Circulation* 1987; 76(4):1216A
7. Roth A, **Barbash GI**, Hod H, Miller HI, Rath S, Modan M, Behar S, Rabinowitz B, Laniado S. Effectiveness and safety of intravenous tissue plasminogen activator thrombolysis by mobile intensive care units in acute myocardial infarction. *J Am Coll Cardiol* 1988; 11(2):187A
8. Miller HI, Roth A, Pardes A, Shagarodsky B, **Barbash GI**, Laniado S. A comparison of early thrombolytic therapy with streptokinase and tissue plasminogen activator in acute myocardial infarction. *Europ Heart J* 1988; 9:215
9. **Barbash GI**, Hod H, Roth A, Miller HI, Rath S, Har-Zahav Y, Agranat O, Modan M, Rabinowitz B, Laniado S, Seligsohn U. Association between fibrinolytic parameters and coronary patency in AMI patients treated by rt-PA thrombolysis. *Circulation* 1988; 78:II-230
10. **Barbash GI**, Roth A, Hod H, Rath S, Miller HI, Kuznitz F, Har-Zahav Y, Agranat O, Modan M, Motro M, Keren G, Battler A, Kaplinsky E, Rabinowitz B, Laniado S. Significance of rapid ST-resolution to predict short and long-term outcome of AMI patients undergoing rt-PA thrombolysis. *Circulation* 1988; 78:II-229
11. Roth A, **Barbash GI**, Hod H, Miller HI, Rath S, Modan M, Behar S, Hadas E, Rabinowitz B, Kaplinsky E, Kuznitz F, Keren G, Laniado S.



- Should rt-PA be administered by the mobile intensive care units teams?  
Circulation 1988; 78:II-187
12. Miller HI, Roth A, Pardes A, Shagarodsky B, **Barbash GI**, Laniado S. No difference in long-term left ventricular function after streptokinase and tissue plasminogen activator therapy in acute myocardial infarction. J Am Coll Cardiol 1989; 13:96A
  13. Hod H, **Barbash GI**, Roth A, Rath S, Miller HI, Battler A, Modan M, Kaplinsky E, Seligsohn U, Laniado S, Rabinowitz B. Safety and efficacy of high dose rt-PA infusion in the treatment of early reinfarction. Europ Heart J 1989; 10:366
  14. **Barbash GI**, Hod H, Roth A, Modan M, Miller HI, Rath S, Har-Zahav Y, Agranat O, Keren G, Motro M, Shachar A, Basan S, Rabinowitz B, Laniado S, Kaplinsky E. Randomized controlled trial of late in-hospital angiography and angioplasty vs. conservative management after rt-PA treatment in acute myocardial infarction. J Am Coll Cardiol 1990; 15:76A
  15. Motro M, Keren G, **Barbash GI**, Hod H, Roth A, Hochenberg M, Shachar A, Rath S, Miller HI, Har-Zahav Y, Kaplinsky E, Laniado S. Prevalence of pericardial effusion and left ventricular thrombi formation following thrombolytic therapy with recombinant tissue plasminogen activator, heparin and aspirin in acute myocardial infarction patients. J Am Coll Cardiol 1990; 15:16A
  16. **Barbash GI**, White H, Van de Werf F. Pre-infarction angina pectoris predicts worse outcome in patients receiving thrombolytic therapy for acute myocardial infarction - experience gathered in the International TPA/STK Study. Europ Heart J 1991; 12:97A
  17. **Barbash GI**, White HD, Van de Werf F. Antecedent angina pectoris predicts worse outcome after thrombolytic therapy for acute myocardial infarction - experience gathered in the International TPA/STK Study. J Am Coll Cardiol 1992; 19:80A
  18. **Barbash GI**, White HD, Van de Werf F. Comparative mortality analysis of the International TPA/STK Trial. An unexplained variance. J Am Coll Cardiol 1992; 19:255A
  19. **Barbash GI**, White H, Modan M, Van de Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993; 21:239A.
  20. Gottlieb S, **Barbash GI**, Khoury Z, Behar S, on behalf of the Israeli Thrombolytic Study Group. Effect of advanced age on use of thrombolytic therapy and mortality in acute myocardial infarction. Europ Heart J 1993; 14:161
  21. **Barbash GI**, for the Israeli investigators. Rescue thrombolysis in reinfarction. Circulation, 1993
  22. **Barbash GI**, for the Israeli Investigators. Rescue thrombolysis in reinfarction. Circulation, 1993;88:I-491

23. Col J, White D, Aylward P, **Barbash GI**, for the GUSTO Trial Investigators. Effects of intravenous versus subcutaneous heparin as adjunctive therapy to streptokinase: results of the GUSTO Trial. *Circulation* 1993;88:I-200
24. White D, **Barbash GI**, Modan M, Simes J, Van de Werf F, for the Investigators of the International rt-PA/Streptokinase Mortality Trial. After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. *Circulation* 1993;88:I-508
25. Behar S, **Barbash GI**, Goldbourt U and the SPRINT and Thrombolytic Study Groups. Have changes in the management of acute myocardial infarction between the 80's and 90's reduced mortality? *Circulation* 1993;88:I-49
26. Behar S, **Barbash GI**, for the Israeli Thrombolytic Surgery Group. Use of coronary procedures in patients with acute myocardial infarction hospitalized in centers with and without coronary angiography facilities in Israel. *J Am Coll Cardiol* 1994;1A:226A
27. **Barbash GI**, White HD, Gore JM, Granger C, Weaver WD, Simoons ML, Aylward P, Van de Werf F, for the GUSTO Trial Investigators. More aggressive thrombolytic treatment increases stroke risk: results from the GUSTO trial. Presented in the American College of Cardiology Meeting, Atlanta, March 1994;1A:28A.
28. Gore JM, **Barbash GI**, White HD, Granger C, Weaver WD, Simoons ML, Aylward P, Vande Werf F, for the GUSTO Trial. status following stroke after thrombolytic therapy-results from the GUSTO trial. Presented in the American College of Cardiology Meeting, Atlanta, March 1994;1A:28A.
29. **Barbash GI**, Ohman EM, White HD, Granger C, Califf RM, for the GUSTO Investigators. Rescue thrombolysis for suspected reinfarction following thrombolytic therapy: experience from the GUSTO trial. Presented in the American College of Cardiology Meeting, Atlanta, March 1994;1A:29A
30. **Barbash GI**, Reiner JS, Granger CB, White HD, Lundergan CF, Ross AM, for the GUSTO Investigators. Smoking and Acute Myocardial Infarction Survival: Demographic and Quantitative Angiographic Foundations for the "Smoker's Paradox". *Circulation* 1994; 90: I-221
31. Gottlieb S, Goldbourt U, **Barbash GI**, Boyko V, Behar S, the SPRINT and the Israeli Thrombolytic Survey Group. The Prognosis of Elderly ( $\geq 75$ ) Patients Hospitalized With Acute Myocardial Infarction From 1981-83 to 1992 in Israel. *Circulation* 1994; 90: I-502
32. White HD, Granger C, Gore J, **Barbash GI**, for the GUSTO Investigators. Older Age is associated With a Large Increase in Mortality and Total Stroke, but Not Non-fatal Disabling Stroke: Results of the GUSTO trial. *Circulation* 1994; 90: I-563

33. Birnbaum Y, Herz I, Sclarovsky S, Zlotikamien B, Chetrit A, **Barbash GI**. Prognostic significance of different patterns of precordial ST segment depression in inferior wall acute myocardial infarction. *Journal of the American College of Cardiology* 1995; 342A.
34. Birnbaum Y, Herz I, Sclarovsky S, Zlotikamien B, Chetrit A, **Barbash GI**. Prognostic significance of the admission ECG in anterior acute myocardial infarction. Laverna Titus Young Investigators Forum, American Heart Association, Greater Los Angeles Affiliate, 1995.
35. Birnbaum Y, Herz I, Zlotikamien B, Sclarovsky S, Chetrit A, **Barbash GI**. Distortion of the terminal portion of the QRS on the admission ECG in acute myocardial infarction: Grave prognostic sign for patients admitted more than two hours after symptoms onset. *J Am Coll Cardiol* 1995; 342A & *Israel J Med Sci* 1996;32:S2
36. Birnbaum Y, Herz I, Sclarovsky S, Zlotikamien B, Chetrit A, **Barbash GI**. The admission electrocardiogram - characteristics identifying a sub-group at increased risk for infarction. *Israel J Med Sci* 1996;32:S2
37. Antman EM, McCabe CH, Cannon CP, **Barbash GI**, Mueller HS, Gallo P. Prevention of Q wave development with thrombolytic therapy does not predict better short-term prognosis. *Circ Abs Suppl* 1996;94:I-381
38. Birnbaum Y, Wagner GS, **Barbash GI**, Gates K, Criger DA, Sclarovsky S, Siegel RJ, Granger CB, Reiner JS, Ross AM. Correlation of angiographic findings and right (V1-V3) versus left (V4-V6) precordial ST-segment depression in inferior-wall acute myocardial infarction. *Journal of the Israel Heart Society Suppl* 1998; Vol. 1, 55.
39. Birnbaum Y, Wagner GS, Thompson TD, **Barbash GI**, Siegel RJ, Fishbein CB MC, Crenshaw BS, Califf RM. Ventricular septal defect in acute anterior wall myocardial infarction: clinical and ECG: variables associated with increased risk. *Journal of the Israel Heart Society Suppl* 1998; Vol 1, 49.
40. Birnbaum Y, Herz I, Zlotikamien B, Strasberg B, Sclarovsky S, Chetrit A, Olmer L, **Barbash GI**. The prognostic implications of negative T waves in the leads with ST segment elevation on admission in acute myocardial infarction. *Journal of the Israel Heart Society Suppl* 1998; Vol 1, 52.
41. Birnbaum Y, Wagner GS, Thompson TD, Gates K, **Barbash GI**, Granger CB, Crenshaw BS, Califf RM.. Ventricular septal defect in acute anterior wall myocardial infarction in the thrombolytic era: electrocardiographic and clinical variables associated with increased risk. *J Am Coll Cardiol* 1999; Vol. 33, 328A.
42. Hudson MP, **Barbash GI**, Granger CB, Birbaum Y, Houbracken K, Pieper KS, Ohman EM, Topol EJ, Califf RM, Van de Werf F. Temporal and regional differences in therapy for reinfarction following thrombolysis: results from GUSTO I and ASSENT II. *JACC*, 2000; 35(2), Suppl A, 386A
43. Birnbaum Y, Iakobishvili Z, Porter A, Strasberg B, Solodky A, Battler A, Criger D, Wagner GS, **Barbash GI**. Prediction of the severity of left

ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram.  
Journal of the Israel Heart Society Suppl. 2000; 22

## H. OTHER PUBLICATIONS

1. Charnilas J, Leitersdorf E, and **Barbash GI**. Evaluation of the helicopter in aeromedical transfers.  
Aviat Space Environ Med (L) 1979; 50(8):846
2. **Barbash GI**, Pollack MA. More snakes (L).  
JAMA 1985; 254:2408-2409
3. **Barbash GI**. Airports medical preparedness for mass disasters.  
J Airport Services Management 1986; 26(4):42-43
4. **Barbash GI**. Preparedness for mass disaster (L).  
Annals Int Med 1986; 104:443
5. **Barbash GI**, Hod H, Ziskind Z, Agranat O, Hirsh R, Smolinsky A. Continuous tissue plasminogen activator infusion to maintain patency of recurrently narrowing coronary artery.  
Lancet 1988; 2:740
6. **Barbash GI**, Keren G, Motro M. Thrombolytic therapy reduces postinfarction left ventricular thrombus risk.  
Cardiology Board Review 1992; 9:52-6
7. **Barbash GI**, White HD, Modan M, Van de Werf F. Smoking and acute myocardial infarction (L). Circulation 1993; 87:1427-8
8. **Barbash GI**, Reiner J, Ross AM, Califf RM. Effect of Smoking Status on Response to Thrombolytic Therapy. JACC 1996;28:283
9. **Barbash GI**, Glied SA. Robot-assisted surgery and health care costs (L)  
N Eng J Med 2010; 363:22:2174-6